Remarkably, measurement of levels of EGFR protein expression or receptor activation (e.g., the presence of activating gene mutations) has not demonstrated any predictive value benefit to cetuximab treatment in HNSCC. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.